Emcure Subsidiary Gennova Divests mRNA Business to Immunoscript for ₹139 Crore to Refocus on Biosimilars
Key Insights
Gennova Biopharmaceuticals (search), an Emcure Pharmaceuticals (search) subsidiary, is selling its mRNA business unit to Immunoscript Life Science (search) for ₹139 crore on a slump sale basis.
The divestiture allows Gennova to sharpen its strategic focus on core operations including biosimilars research, development, and manufacturing.
The mRNA unit, which developed India's first mRNA vaccine during COVID-19 (search), contributed only ₹6.47 crore in revenue, representing 0.71% of Emcure's consolidated revenue.
Emcure Pharmaceuticals (search) has announced that its biotech subsidiary, Gennova Biopharmaceuticals (search), has entered into a business transfer agreement to sell its mRNA-focused business unit to Immunoscript Life Science (search) Private Limited. The deal, valued at ₹139 crore, is structured as a slump sale and is expected to be completed by July 17, 2026.
The divested unit gained national prominence during the COVID-19 (search) pandemic for developing India's first and only mRNA vaccine. Despite this scientific achievement, the mRNA business generated revenue of just ₹6.47 crore, accounting for approximately 0.71% of Emcure's consolidated revenue of ₹911.58 crore.
Strategic Reorganization Toward Core Strengths
Emcure stated that "the transfer of mRNA business is part of Gennova's strategic initiative to reorganise its business operations and focus on core areas – research and development, manufacturing and marketing of biotechnology based products including biosimilars and adjacent therapeutic platforms." By shedding the mRNA division, Gennova aims to dedicate its resources more effectively toward biosimilars and other biotechnology products, which represent the company's primary growth drivers.
The transaction is being executed as a slump sale through a business transfer agreement rather than a court-approved scheme of arrangement, a structure that allows for a more streamlined transfer of the business as a going concern.
Buyer Profile and Future Direction
The acquirer, Immunoscript Life Science (search), is a newly incorporated entity founded in April 2026. The company is promoted by Sanjay Singh, who previously served as a director at Gennova Biopharmaceuticals (search). Immunoscript has outlined a business model centered on precision immunology, with plans to integrate artificial intelligence, biological engineering, and scalable biomanufacturing technologies to accelerate the development of next-generation vaccines and advanced therapeutics.
Financial and Investor Implications
For investors, the primary takeaway is Emcure's effort to streamline its portfolio by exiting a non-core, lower-contribution business segment. While the sale brings in ₹139 crore in cash, the financial impact on the consolidated top line remains limited given the small revenue share of the divested unit. Stakeholder attention will now shift to the completion of the transfer by the July 2026 deadline and any subsequent updates from management regarding the allocation of proceeds, particularly whether the capital will be reinvested into core biosimilar projects or directed toward other financial priorities.